Home Corporate

Corporate

Silverback Raises U.S. $78.5 Million to Advance SBT6050 into the Clinic for HER2-expressing Solid...

Seattle-based Silverback Therapeutics™, a biopharmaceutical company pioneering a new class of immune-modulating ImmunoTAC™ drug conjugates targeting previously inaccessible disease...

Loretta Itri, M.D., Joins Immunomedics as Chief Medical Officer

Biotech company Immunomedics today confirmed the appointment of Loretta Itri, M.D. as Chief Medical Officer (CMO). In her new...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Navrogen and Levena to Develop Novel ADC for the Treatment of Humoral Immuno-Suppressed Cancers

Biopharmaceutical company Navrogen, specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, have agreed to collaborate...
Featured Image: London Tower Bridge. Photo Courtesy: 2018 Fotolia

Zymeworks, Regeneron, Boehringer Ingelheim Pharma and Many Others are Betting on Antibody-Drug-Conjugates

Antibody-Drug -Conjugates (ADCs) have the potential to reduce off-target toxicities in patients by limiting the exposure of normal tissues...
The AACR 2019 Annual Meeting - Poster Session during the American Association for Cancer Research (AACR) Annual Meeting, Sunday March 31, 2019. Courtesy: © AACR/Todd Buchanan 2019

Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics

Veteran Executive Randall Schatzman, Ph.D. has been hired as the new Chief Executive Officer and a member of the...
WuXi Biologics. 1,000 LX2 disposable bioreactors for perfusion processes.

Single-layer Film Bags vs. Multi-layer Film Bags Biopharmaceutical Manufacturing

Since the early 1970s, single-use, disposable plastic technology for the manufacturing of biopharmaceutical products according to the U.S. Food...

X